The National Institutes of Health (NIH) is seeking sources to provide proteomic biomarker testing services using the CNS panel 220 Argo NULISA platform for Alzheimer’s disease research. The contractor must process up to 8,970 biospecimens annually across a base year (August 1, 2026 – July 31, 2027) and two option years, with a weekly throughput capacity of 2,400 samples. Performance will take place at the contractor’s facility, with deliverables including raw sequencing data within two weeks and final QC-reviewed results within four weeks of sample processing. No budget amounts are specified in this sources sought notice.